Stocktoria
Keros Therapeutics, Inc. KROS
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-04-08
Keros Therapeutics, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $244.1M | $3.5M | $151,000 | $0 | $20.1M | $0 | $10.0M |
| R&D expense | $129.6M | $173.6M | $135.3M | $87.3M | $55.1M | $33.9M | $17.4M |
| Operating income | $67.6M | -$210.8M | -$169.9M | -$114.8M | -$56.4M | -$46.7M | -$10.6M |
| Income tax | $4.9M | $300,000 | $0 | $0 | $2.0M | -$172,000 | $0 |
| Net income | $87.0M | -$187.4M | -$153.0M | -$104.7M | -$58.7M | -$45.4M | -$12.3M |
| EPS (diluted) | $2.30 | $-5.00 | $-5.20 | $-4.15 | $-2.52 | $-2.93 | — |
| Operating cash flow | $107.5M | -$160.9M | -$124.5M | -$70.1M | -$62.1M | -$36.9M | -$16.0M |
| Free cash flow | $106.0M | -$162.8M | -$127.0M | -$71.3M | -$63.2M | -$37.2M | -$16.3M |
| Cash & equivalents | $287.4M | $559.9M | $331.1M | $279.0M | $230.0M | $265.9M | $7.0M |
| Total assets | $338.0M | $615.9M | $370.0M | $306.8M | $255.3M | $269.4M | $11.0M |
| Total liabilities | $34.9M | $44.3M | $37.8M | $29.4M | $12.1M | $7.7M | $10.5M |
| Shareholders' equity | $303.1M | $571.6M | $332.2M | $277.4M | $243.2M | $261.7M | -$19.4M |
Growth · year-over-year · Revenue CAGR 70.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +6775.0% | +2251.0% | — | -100.0% | — | -100.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.